2020年9月17日，深圳证券交易所内钟声回荡，稳健医疗（300888.SZ）正式挂牌创业板，成为中国大健康产业中一家兼具医疗内核与消费特色的上市公司。 韧性增长：结构优化与战略协同的双重奏鸣 2025年上半年，面对复杂多变的全球经贸环境和国内消费市场波动，稳健医疗展现出较强的抗周期能力。报告期内，公司实现营业收入53.0亿元，同比增长 31.3%；归属于上市公司股东净利润4.9亿元，扣除非经常性损益后净利润4.6亿元，同比增幅分别达到28.1%和40.9%。这份成绩的背后，是医疗与消费两大 业务板块高效协同、彼此赋能的战略成果。 医疗板块作为公司发展的根基，在"内生提速，外延并购"的双重策略推动下，2025年上半年实现营业收入25.2亿元，同比增长46.4%，其中第二季度单季营 收达到12.6亿元，增速高达46.5%。这一显著增长，一方面源于感染防护与伤口护理等传统产品线的需求企稳，另一方面则得益于手术室耗材、高端敷料等 高附加值产品在海外市场的快速扩张。 特别值得一提的是公司在美国及加勒比地区的产能布局——通过并购美国GRI公司以及扩建多米尼加近岸生产基地，稳健医疗有效构建了"本土制造+近岸供 应"的全球 ...

Core Viewpoint - The article discusses the operational and strategic developments of Shengjian Medical, highlighting its focus on automation, internationalization, and brand development in the medical and consumer sectors. Group 1: Company Operations - Shengjian Medical's Wuhan production base operates three production lines with a monthly capacity of 1,500-1,600 tons [4] - The company has achieved a high level of automation, resulting in a "dark factory" model where minimal staff is required [3] - The medical segment's revenue for the first half of 2025 reached 25.2 billion yuan, a year-on-year increase of 46.4% [6] Group 2: Financial Performance - In the first half of 2025, Shengjian Medical reported a revenue of 52.96 billion yuan and a net profit of 4.92 billion yuan, reflecting year-on-year growth of 31.31% and 28.07% respectively [6] - The consumer segment, represented by "Cotton Era," achieved a revenue of 27.5 billion yuan in the same period, growing by 20.3% [6] - The company's profit margin is currently around 9%, lower than the previous 12% level [7] Group 3: Strategic Goals - Shengjian Medical aims to increase its international brand presence, targeting a shift from 10% to 90% in self-owned brand sales in overseas markets over the next five years [4] - The company plans to enhance its product structure by focusing on high-end medical materials and expanding its consumer product lines [8] - Future growth points include expanding the "Cotton Era" brand into new product categories and international markets [10][14] Group 4: Market Expansion - Shengjian Medical's overseas sales revenue reached 14.3 billion yuan in the first half of 2025, marking an 81.3% increase [13] - The company has successfully penetrated markets in North America, Europe, and Asia, with its products gaining significant market share [13] - The company is cautious about overseas listings, focusing instead on domestic market growth and brand recognition [15]

Core Insights - The company has transformed from being labeled as a "pandemic beneficiary stock" to a global health platform covering both medical and consumer sectors, demonstrating resilience against industry cyclicality [2][3] - In 2024, the company reported a revenue of 8.978 billion yuan, a year-on-year increase of 9.7%, with core business revenue growth of 18.6% after excluding high-volatility products [3][4] - The company has invested over 1.8 billion yuan in R&D, with a total of 986 patents granted, showcasing its commitment to innovation and technology [2][6][7] Financial Performance - The company has maintained a strong cash flow, returning 3.57 billion yuan to shareholders through dividends and share buybacks since its IPO, exceeding the net proceeds from its initial public offering [4][5] - The company has implemented six cash dividends totaling 2.613 billion yuan and has initiated mid-term dividends in 2024 and 2025, reflecting its financial stability and commitment to shareholder returns [4][5] Product and Market Development - The medical segment has seen significant growth, with high-end dressings and surgical consumables driving revenue, particularly a 193.5% increase in surgical consumables revenue in the first half of 2025 [3][6] - The consumer segment has also performed well, with core products like cotton soft towels and sanitary napkins showing year-on-year revenue growth of 19.5% and 67.6%, respectively [3][6] Technological Advancements - The company has established three R&D centers and a team of 1,360 researchers, focusing on a closed-loop system of basic research, scenario transformation, and brand guidance [6][7] - The company has developed proprietary technologies, such as the all-cotton water-jet non-woven fabric, and has participated in setting national standards, enhancing its industry position [6][7] Global Expansion - The acquisition of GRI Holdings in 2024 marks a shift in the company's global strategy from product export to localized manufacturing, sales, and service [10][11] - The overseas sales channels achieved a revenue of 1.43 billion yuan in the first half of 2025, a year-on-year increase of 81.3%, indicating strong international growth [10][11] Long-term Vision - The company emphasizes sustainable practices, collaborating with research institutions to develop cotton varieties, ensuring a continuous supply of high-quality raw materials [12][13] - The company's evolution reflects a shift from OEM to building its own brand, focusing on quality and social value over short-term profits [13][14]

Investment Rating - The report maintains a "Buy" rating for the company with a target price not specified [7][6]. Core Insights - The company reported a strong performance in H1 2025, achieving revenue of 5.3 billion yuan, a year-on-year increase of 31%, and a net profit of 490 million yuan, up 28% year-on-year [1]. - The consumer goods segment showed robust growth, with revenue from the core product, wet and dry cotton towels, reaching 810 million yuan, a 19.5% increase year-on-year [2]. - The medical supplies segment also performed well, with total revenue of 2.52 billion yuan in Q2 2025, reflecting a 46.5% year-on-year growth [3]. Financial Performance - For H1 2025, the company achieved a gross margin of 48.3%, slightly down by 0.4 percentage points year-on-year, and a net margin of 9.8%, down by 0.3 percentage points [1]. - The consumer goods segment's gross margin improved to 58.6%, up 1.7 percentage points year-on-year, while the medical segment's gross margin decreased to 37.4%, down 0.7 percentage points [4]. - The company reported a net operating cash flow of 340 million yuan, indicating stable operational fundamentals [1]. Business Segments - The consumer goods business generated revenue of 2.75 billion yuan in H1 2025, a 20.3% increase year-on-year, with a notable performance from the "Nais Princess" sanitary napkin line, which saw a 67.6% increase in revenue [2]. - The medical supplies segment's revenue reached 2.52 billion yuan in Q2 2025, with surgical supplies and high-end dressings showing significant growth rates of 193.5% and 25.7% respectively [3]. Channel Strategy - The company has accelerated its omnichannel strategy, with online sales reaching 1.71 billion yuan, a 23.6% increase year-on-year, and offline stores contributing 724 million yuan, up 2.75% [5]. - The total number of offline stores reached 484, with a membership base of nearly 67 million, reflecting continued brand penetration [5]. Earnings Forecast - The report adjusts the earnings forecast, projecting net profits of 1.04 billion yuan, 1.26 billion yuan, and 1.49 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 1.79 yuan, 2.16 yuan, and 2.56 yuan [6].

Core Viewpoint - The company, Steady Medical, has reported strong financial results for the first half of 2025, driven by its dual focus on the medical and consumer sectors, with significant year-on-year growth in both revenue and profit [2][4]. Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 5.3 billion yuan, representing a year-on-year increase of 31.3% [2]. - The net profit attributable to shareholders reached 490 million yuan, up 28.1% year-on-year, while the net profit excluding non-recurring items was 460 million yuan, reflecting a growth of 40.9% [2]. - The medical segment contributed 2.52 billion yuan, while the consumer segment generated 2.75 billion yuan in revenue [2]. Group 2: Medical Segment Recovery - The medical segment, primarily under the "Steady Medical" brand, reported revenue of 2.52 billion yuan, a year-on-year increase of 46.4% [4]. - Excluding the contribution from the acquired company GRI, the medical segment achieved 1.95 billion yuan in revenue, marking a 13.2% increase compared to the same period in 2024 [4]. - The management expressed optimism about the medical segment's future growth, citing a stable increase in the aging population and a projected compound annual growth rate of approximately 6% in the medical consumables sector from 2024 to 2030 [4]. Group 3: Consumer Segment Growth - The consumer segment, centered around the "All Cotton Era" brand, generated 2.75 billion yuan in revenue, reflecting a year-on-year growth of 20.3% [7]. - Key products included cotton soft towels with revenue of 810 million yuan (up 19.5%), "Princess Nais" sanitary napkins with 530 million yuan (up 67.6%), and adult apparel with 520 million yuan (up 19.4%) [7]. - The high-margin "Princess Nais" sanitary napkin product significantly contributed to the overall gross margin increase of 1.7 percentage points to 58.6% [7]. Group 4: Marketing and Distribution Strategy - The company invested heavily in marketing, with advertising and promotional expenses reaching 501 million yuan, a 47.59% increase year-on-year [8]. - Online sales channels generated 1.71 billion yuan in revenue, up 23.6% year-on-year, indicating a strong focus on e-commerce [8]. - The company is adopting a cautious yet optimistic strategy for its offline store expansion, closing underperforming stores while opening new ones in high-potential areas [9]. Group 5: Dividend and Share Buyback - The company announced a cash dividend distribution plan of 260 million yuan, which accounts for 53.26% of the net profit attributable to shareholders [9]. - Since its listing, the company has distributed a total of 2.88 billion yuan in cash dividends and repurchased shares for 690 million yuan, totaling 3.57 billion yuan, which exceeds 100% of its net fundraising amount [9].

Investment Rating - The investment rating for the company is "Outperform the Market" [5][34]. Core Insights - The company achieved a revenue growth of 31.3% year-on-year in the first half of 2025, reaching 5.3 billion yuan, with a net profit increase of 28.1% to 490 million yuan [9][34]. - The medical segment saw a significant revenue increase of 46.4% to 2.52 billion yuan, while the consumer goods segment grew by 20.3% to 2.75 billion yuan [9][10]. - The company is focusing on integrating its medical business and expanding its market share, supported by strong cash flow and a good dividend level [34]. Summary by Sections Financial Performance - In the first half of 2025, the company's revenue increased by 31.3% to 5.3 billion yuan, and net profit rose by 28.1% to 490 million yuan [9][34]. - The gross profit margin remained stable overall, with the medical business's gross margin decreasing by 0.7 percentage points to 37.4%, while the consumer goods segment's gross margin improved by 1.7 percentage points to 58.6% [20][34]. Medical Segment - The medical segment's revenue for the first half of 2025 was 2.52 billion yuan, a year-on-year increase of 46.4%. Excluding the contribution from the newly acquired GRI, the revenue grew by 13.2% to 1.95 billion yuan [9][30]. - Key growth drivers included surgical consumables, which surged by 193.5% to 740 million yuan, and stable growth in high-end dressings and health personal care products [3][30]. Consumer Goods Segment - The consumer goods segment reported a revenue increase of 20.3% to 2.75 billion yuan, with core products like sanitary napkins leading the growth, achieving a 67.6% increase to 530 million yuan [10][34]. - The company experienced a decline in the number of stores, closing three to a total of 484, while online sales grew by 23.6% to 1.71 billion yuan [10][34]. Future Outlook - The company has slightly adjusted its profit forecast for 2025-2027, expecting net profits of 1.01 billion, 1.17 billion, and 1.35 billion yuan respectively, with growth rates of 44.7%, 16.1%, and 15.5% [34]. - The target price has been revised to 48-52 yuan, corresponding to a PE ratio of 24-26x for 2026 [34].

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [1] Core Views - The company reported strong growth in its 2025 mid-year results, driven by dual business segments: consumer products and medical supplies. The revenue for the first half of 2025 reached 5.296 billion yuan, a year-on-year increase of 31.31%, while the net profit attributable to shareholders was 492 million yuan, up 28.07% year-on-year [7] - The consumer products segment showed robust performance, with revenue of 2.745 billion yuan in the first half of 2025, a year-on-year increase of 20.3%. The company experienced significant growth in its core product categories, particularly in sanitary napkins and cotton soft towels [7] - The medical supplies segment also performed well, with revenue of 2.515 billion yuan in the first half of 2025, a year-on-year increase of 46.39%. The company is focusing on internal growth and mergers to enhance its market position [7] - The company has adjusted its profit forecasts for 2025-2027, increasing the net profit estimates to 1.045 billion yuan, 1.237 billion yuan, and 1.494 billion yuan respectively, corresponding to P/E ratios of 23, 20, and 16 [7] Financial Summary - Total revenue for 2023 is projected at 8.185 billion yuan, with a year-on-year decrease of 27.89%. However, revenue is expected to grow to 11.219 billion yuan in 2025, reflecting a year-on-year increase of 24.96% [1][8] - The net profit attributable to shareholders is forecasted to rise from 580.4 million yuan in 2023 to 1.045 billion yuan in 2025, representing a year-on-year growth of 50.21% [1][8] - The latest diluted EPS is expected to increase from 1.00 yuan in 2023 to 1.79 yuan in 2025 [1][8] - The company's cash flow from operating activities for the first half of 2025 was 340 million yuan, a year-on-year increase of 75.82%, indicating strong cash generation capabilities [7]

Core Insights - The company has conducted investor relations activities, attracting significant institutional interest [1] - In the first half of the year, the company demonstrated strong performance with a net profit of 490 million yuan, representing a year-on-year increase of 28.1% [1] - The company maintains a product leadership strategy with a steady increase in patent and medical product registration certificates [1] Financial Performance - The net profit attributable to shareholders reached 490 million yuan, with a net profit of 460 million yuan after deducting non-recurring gains, marking year-on-year growth of 28.1% and 40.9% respectively [1] - Cumulative cash dividends amount to 2.88 billion yuan, with share buybacks totaling 690 million yuan, together accounting for 100.3% of the net proceeds from the initial public offering [1] Business Segments - The medical consumables business saw a year-on-year increase of 13.2%, with the second quarter's revenue growing by 15.3% compared to the previous year [2] - The consumer goods segment, particularly the "All Cotton Era" brand, achieved revenue of 2.75 billion yuan, reflecting a year-on-year growth of 20.3% [2] - The company has expanded its offline stores to 484, with 16 new openings in the first half of the year, and the total membership has grown to nearly 67 million, a 7.7% increase from the end of last year [2] Market Activities - The company actively participated in exhibitions and promotional activities, including the 91st China International Medical Equipment Expo and the third China International Supply Chain Promotion Expo [2] - A special program was launched in collaboration with CCTV to enhance brand image in the consumer healthcare sector [2]

Financial Performance - In the first half of 2025, the company achieved a total revenue of 5.3 billion yuan, representing a year-on-year growth of 31.3% [11] - The revenue for Q1 and Q2 was 1.9 billion yuan and 2.6 billion yuan respectively, showing a steady increase [12] - The overall gross profit margin remained stable, with the operating profit margin increasing by 0.7 percentage points compared to the same period last year [16] Profitability - The net profit attributable to shareholders was 490 million yuan, with a year-on-year growth of 28.1% [16] - The net profit excluding non-recurring gains and losses was 460 million yuan, reflecting a growth of 40.9% [16] - The company's asset-liability ratio decreased to 32%, indicating improved asset quality [18] Business Segments Medical Consumables - The medical segment generated a revenue of 2.52 billion yuan, with a year-on-year increase of 46.4% [29] - Excluding the contribution from the newly acquired GRI, the revenue was 1.95 billion yuan, up 13.2% year-on-year [29] - Key product categories such as surgical consumables and high-end dressings showed strong growth [29] Consumer Products - The consumer segment achieved a revenue of 2.75 billion yuan, growing by 20.3% year-on-year [40] - The core product, the Nai Si Princess sanitary napkin, significantly contributed to the overall growth [40] - The online sales channel generated 1.71 billion yuan, with a year-on-year increase of 23.6% [45] R&D and Innovation - The company emphasized R&D investment, with a steady increase in the number of patents and medical product registrations [18] - The focus on product innovation led to the development of high-end materials and improved product offerings [25][35] Shareholder Returns - The mid-term profit distribution plan for 2025 includes a cash dividend of 4.5 yuan per 10 shares, totaling 260 million yuan, which is 53% of the net profit attributable to shareholders [23] - Cumulatively, the company has distributed 2.88 billion yuan in cash dividends since its listing [23]

Investment Rating - The report initiates coverage with a "Buy" rating for the company [6]. Core Insights - The company reported a 31.3% year-on-year increase in revenue for H1 2025, reaching 5.3 billion yuan, and a 28.1% increase in net profit attributable to shareholders, amounting to 490 million yuan [2]. - The medical business showed robust growth, with H1 2025 revenue up 46% to 2.52 billion yuan, while the consumer goods segment grew 20.3% to 2.75 billion yuan [3][4]. - The company maintains stable profitability, with a slight decline in gross margin to 48.3% and a net profit margin of 9.8% for H1 2025 [4]. Revenue and Profit Forecast - Projected revenue growth for 2025-2027 is 24.3%, 14.9%, and 12.8%, reaching 11.16 billion, 12.82 billion, and 14.46 billion yuan respectively [4]. - Expected net profit growth for the same period is 44.2%, 23.9%, and 19.1%, resulting in net profits of 1 billion, 1.24 billion, and 1.48 billion yuan [4]. Financial Metrics - The company’s gross margin for the medical and consumer goods segments is 37.4% and 58.6% respectively, with the consumer goods margin benefiting from lower cotton prices and improved product mix [4]. - The company plans to distribute a cash dividend of 4.5 yuan per 10 shares, with a payout ratio of 53.3% [4]. Market Performance - The stock closed at 42.09 yuan, with a 12-month price range of 23.45 to 53.75 yuan [6]. - The company has a total market capitalization of approximately 24.51 billion yuan [6].